Clinical trials: Refractory Autoimmune Diseases
Juvenile Rheumatoid Arthritis
Effect of Electroacupuncture on Refractory Pain in Juvenile Rheumatoid Arthritis: Randomized Controlled Trial
the purpose of the study is to investigate the effect of Electrical Acupuncture Versus naproxen phonophoresis on Refractory pain in Juvenile Rheumatoid arthritis
- Trial name
- NCT05504382
- Testing
- naproxen phonophoresis
- Where
- Egypt
- Volunteers
- 42 people
- Sponsor
- Mohamed Abdelmoneim El Meligy
Inherited Mitochondrial Disease
A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial Disease
The primary objective of this study is to assess the safety of vatiquinone in participants with inherited mitochondrial disease who had prior exposure to vatiquinone in a PTC/BioElectron sponsored (previously Edison) clinical…
- Trial name
- NCT05218655
- Testing
- Vatiquinone
- Where
- 26 sites in United States, France and 5 more
- Volunteers
- 101 people
- Sponsor
- PTC Therapeutics
Autoimmune Diseases, SLE - Systemic Lupus Erythematosus
RD06-05 Universal CD19/BCMA CAR-T for Refractory Pediatric Autoimmune Diseases
This is a single-arm, open-label, phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of RD06-05, a universal CD19/BCMA dual-targeting chimeric antigen receptor T-cell…
- Conditions
- Autoimmune Diseases, SLE - Systemic Lupus Erythematosus, SSc-Systemic Sclerosis, IIM- Idiopathic Inflammatory Myopathies
- Trial name
- NCT07674147
- Testing
- RD06-05 CART Cell Infusion
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Refractory Myasthenia Gravis
Allogeneic CD19-CAR-NK Cells in Patients With Refractory Myasthenia Gravis
This study is a single-center, prospective, nonrandom, single-arm trial.
- Trial name
- NCT07243366
- Testing
- CD19-CAR-NK Cells Injection
- Volunteers
- 15 people
- Sponsor
- Guangdong ProCapZoom Biosciences Co., Ltd.
Refractory Systemic Juvenile Idiopathic Arthritis, Systemic Juvenile Idiopathic Arthritis
Allogeneic Hematopoietic Cell Transplantation for Refractory Systemic Juvenile Idiopathic Arthritis.
The goal of this study is to collect clinical data and samples and to evaluate the feasibility of allogeneic hematopoietic cell transplantation (HCT) in children and young adults with refractory Systemic Juvenile Idiopathic…
- Conditions
- Refractory Systemic Juvenile Idiopathic Arthritis, Systemic Juvenile Idiopathic Arthritis, Systemic Juvenile Idiopathic Arthritis Associated Lung Disease
- Trial name
- NCT07845942
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Lupus Nephritis, Lupus Nephritis (LN)
Study to Evaluate the Safety and Preliminary Efficacy of CD19 CAR-T Cell Therapy (TranspoCART19) in Patients With Refractory Lupus Nephritis
The goal of this clinical trial is to evaluate the safety and preliminary efficacy of CD19 CAR-T cell therapy (TranspoCART19) in adults with refractory lupus nephritis.
- Trial name
- CART-NEL (NCT07799116)
- Testing
- TranspoCART19
- Where
- 8 sites in Spain
- Volunteers
- 10 people
- Sponsor
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
Refractory Cold Agglutinin Disease
Short Course of Bortezomib in Anemic Patients With Refractory Cold Agglutinin Disease
This multicenter, phase II, open label study will enroll patients with chronic cold agglutinin disorder. A single course of Bortezomib will be given at the dose of 1,3 mg/sqm iv on days 1, 4, 8, 11.
- Trial name
- CAD0111 (NCT01696474)
- Testing
- Bortezomib
- Where
- 8 sites in Italy
- Volunteers
- 21 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Rheumatoid Arthritis
Sacral Nerve Stimulation for Mild-to-Moderate or Refractory Rheumatoid Arthritis
This pilot study will assess the efficacy of sacral never stimulation (SNS) for the treatment of adult patients with active, mild-to-moderate rheumatoid arthritis or those with refractory disease.
- Trial name
- NCT04821050
- Testing
- Sacral nerve stimulation
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Autoimmune Hemolytic Anemia, Autoimmune Hemolytic Anemia and Autoimmune Thrombocytopenia
Single-dose Anti-CD20 Antibody With Bortezomib for Relapsed Refractory Autoimmune Hemolytic Anemia
Patients of relapsed and refractory warm autoimmune hemolytic anemia or EVANS syndrome aged 18 to 80 will be included in this study.
- Trial name
- RRAIHA01 (NCT04083014)
- Testing
- combination of a single dose anti-CD20 antibody and bortezomib
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Peking Union Medical College Hospital
Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome
Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune Disease
This is an investigator-initiated trial to evaluate the safety and efficacy of anti-CD19-CD3E-CAR-T cells in the relapse or refractory autoimmune diseases.
- Conditions
- Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome, Systemic Sclerosis, Inflammatory Myopathy
- Trial name
- NCT06373081
- Testing
- Anti-CD19-CD3E-CAR-T cells
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Shanghai Changzheng Hospital
Generalized Myasthenia Gravis (gMG), Refractory gMG
Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Eculizumab in Chinese Adults With gMG
This is an open-label, single-arm, multi-center study to evaluate the efficacy, safety, PK, PD, and immunogenicity of eculizumab in Chinese participants with refractory gMG.
- Trial name
- ECU-MG-304 (NCT06764160)
- Testing
- Eculizumab
- Where
- 6 sites in China
- Volunteers
- 15 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Myasthenia Gravis
Blinatumomab for Treatment of Refractory Myasthenia Gravis
The goal of this clinical trial is to evaluate the efficacy and safety of Blinatumomab in the treatment of refractory myasthenia gravis, with the expectation of offering a new therapeutic option for refractory patients.
- Trial name
- NCT06836973
- Testing
- Blinatumomab
- Volunteers
- 2 people
- Sponsor
- Da, Yuwei, M.D.
Abatacept, Treatment Compliance
Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis
The aim of this study is to observe the clinical efficacy and safety of abatacept combined with JAK inhibitor in the treatment of D2TRA patients
- Conditions
- Abatacept, Treatment Compliance, Rheumatoid Arthritis
- Trial name
- NCT05451615
- Testing
- Janus Kinase Inhibitor, Abatacept
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Zhejiang Provincial People's Hospital
Neurological Autoimmune Diseases
A Study of CNCT19 in the Treatment of Relapsed or Refractory Neurological Autoimmune Diseases
This study is a single-arm, open-label, non-randomized clinical trial aimed at evaluating the safety, tolerability and preliminary efficacy of CNCT19 cell injection in the treatment of patients with relapsed/refractory…
- Trial name
- NCT07275736
- Testing
- CNCT19 cell injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Juventas Cell Therapy Ltd.
Refractory Membranous Nephropathy
Safety and Efficacy of CD19 Chimeric Antigen Receptor T-Cell (CAR-T) in the Treatment of Refractory Membranous Nephropathy
This study is a single-center, prospective, exploratory Phase I clinical trial initiated by the team led by Associate Professor He Lijie from the Department of Nephrology, Xijing Hospital.
- Trial name
- NCT07266181
- Testing
- All patients will receive CD19 CAR-T cell therapy on the basis of standard symptomatic and supportive treatment.
- Where
- China
- Volunteers
- 5 people
- Sponsor
- The First Affiliated Hospital of Air Force Medical University
Autoimmune Disease
Safety and Efficacy of CD19 CAR-T Therapy for Recurrent/Refractory Autoimmune Diseases
This study is a single center, open label exploratory clinical trial aimed at evaluating the safety and efficacy of universal CD19 CAR-T therapy in subjects with autoimmune diseases.
- Trial name
- NCT06983964
- Testing
- CD19 CART
- Where
- China
- Sponsor
- Beijing Boren Hospital
Chronic Lymphocytic Leukemia
Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia (CLL) That Did Not Respond to Fludarabine, CLL With Autoimmune Haemolytic Anemia (AIHA) or Richter's Transformation (RT)
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00309881
- Testing
- rituximab, cyclophosphamide, doxorubicin hydrochloride
- Where
- 18 sites in Germany
- Volunteers
- 75 people
- Sponsor
- German CLL Study Group
Sjogren's Syndrome, Autoimmune Diseases
A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Sjogren's Syndrome
A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Sjogren's Syndrome
- Trial name
- NCT05085431
- Testing
- Assigned Interventions CD19/BCMA CAR T-cells
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Zhejiang University
Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc)
CT1190B in the Treatment of Patients With Moderate to Severe Refractory Systemic Lupus Erythematosus (SLE) or Refractory/Progressive Systemic Sclerosis (SSc)
A Clinical Study Exploring CT1190B in the treatment of patients with moderate to severe refractory systemic lupus erythematosus (SLE) or refractory/progressive systemic sclerosis (SSc)
- Trial name
- NCT06822881
- Testing
- CAR-T Therapy
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Beijing GoBroad Hospital
Autoimmune Diseases
An Exploratory Clinical Study of SCAR02 Targeting BCMA and CD19 for the Treatment of Refractory Autoimmune Diseases
This is an open label, single-site, dose-escalation study in up to 18 participants with refractory autoimmune diseases. This study aims to evaluate the safety and efficacy of the treatment with Anti-BCMA and CD19 CART
- Trial name
- SCAR02 (NCT06503224)
- Testing
- Anti-BCMA and CD19 CART cells will be injected intravenously on a one-time basis.
- Where
- China
- Volunteers
- 18 people
- Sponsor
- The First Affiliated Hospital of University of Science and Technology of China